Abrdn Life Sciences Investors (NYSE:HQL) Short Interest Up 212.4% in December

Abrdn Life Sciences Investors (NYSE:HQL) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 77,800 shares, a growth of 212.4% from the December 15th total of 24,900 shares. Based on an average trading volume of 93,900 shares, the short-interest ratio is currently 0.8 days.

Abrdn Life Sciences Investors Price Performance

Shares of HQL stock opened at $13.37 on Tuesday. The business’s fifty day moving average price is $14.00 and its 200 day moving average price is $14.68. Abrdn Life Sciences Investors has a 1-year low of $12.76 and a 1-year high of $15.90.

Abrdn Life Sciences Investors Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 10th. Investors of record on Thursday, November 21st were issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 14.96%. The ex-dividend date of this dividend was Thursday, November 21st. This is a positive change from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.49.

Institutional Trading of Abrdn Life Sciences Investors

Large investors have recently bought and sold shares of the company. Future Financial Wealth Managment LLC acquired a new stake in Abrdn Life Sciences Investors in the third quarter valued at $30,000. Ashton Thomas Securities LLC acquired a new stake in Abrdn Life Sciences Investors in the third quarter valued at $148,000. Sanctuary Advisors LLC purchased a new stake in shares of Abrdn Life Sciences Investors in the second quarter valued at $154,000. Kapstone Financial Advisors LLC purchased a new stake in shares of Abrdn Life Sciences Investors in the third quarter valued at $177,000. Finally, Stephens Inc. AR lifted its position in shares of Abrdn Life Sciences Investors by 7.6% in the third quarter. Stephens Inc. AR now owns 12,707 shares of the company’s stock valued at $192,000 after acquiring an additional 896 shares in the last quarter. Institutional investors and hedge funds own 32.21% of the company’s stock.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.